Current and future therapies of hepatitis C. (Q34269634)

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Therapy of hepatitis C: re-treatment with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Epidemiology of hepatitis C in the West

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Epidemiology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

The epidemiology of acute and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Hepatitis C and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Ribavirin: a clinical overview

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Hepatitis C virus viremia following clinical resolution of acute hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Hepatitis C virus: epidemiology and transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Hepatitis C: the clinical spectrum of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Prolonged therapy of chronic hepatitis C with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Interferon treatment of cirrhotic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Therapy of hepatitis C: cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Effect of immune globulin on the prevention of experimental hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Therapy of hepatitis C: interferon alfa-2a trials

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Hepatitis C: the clinical spectrum of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Treatment of chronic hepatitis C by interferon for longer duration than six months

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Interferon-ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

The long-term pathological evolution of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021

Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970169-0

7 January 2021